The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.

Expert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.

The Brazilian Journal of Pharmaceutical Sciences is a prestigious and peer-reviewed journal dedicated to disseminating significant research across the fields of Pharmacology, Toxicology, and Pharmaceutics. Published by UNIV SAO PAULO, CONJUNTO QUIMICAS, this journal has been an Open Access platform since 2009, making it accessible to a global audience, fostering collaboration and knowledge sharing among researchers and professionals. With an ISSN of 1984-8250 and an E-ISSN of 2175-9790, it holds a respectable Q3 ranking in these fields for 2023, indicating its contribution to the scientific community's understanding and advancement of pharmaceutical sciences. As it converges from 2009 to 2024, the journal continues to address emerging trends and critical topics in drug development, safety, and efficacy, positioning itself as an essential resource for students, researchers, and practitioners seeking to contribute to and stay informed about advancements in pharmacological research. With its publication address in São Paulo, Brazil, the journal serves as a key outlet for Brazilian and international scholars alike.

Cancer Nanotechnology is a cutting-edge peer-reviewed journal dedicated to advancing the field of cancer research through innovative nanotechnology applications. Published by SPRINGER WIEN, this open-access journal, established in 2010, provides a vital platform for the dissemination of high-quality research with a focus on the intersection of nanotechnology, oncology, and biomedical engineering. With a commitment to promoting accessibility and fostering collaboration, Cancer Nanotechnology has gained impressive rankings within specialized categories, including Q2 in Biomedical Engineering and Pharmaceutical Science. The journal's rigorous selection process ensures that only the most impactful studies reach its audience, making it a must-read for researchers, professionals, and students eager to explore the latest advancements and methodologies in cancer treatment. With its scope encompassing critical topics that bridge multiple disciplines—including physical chemistry and toxicology—Cancer Nanotechnology positions itself as an influential resource for shaping the future of cancer therapies.

Current Drug Delivery, published by Bentham Science Publishers Ltd, serves as a vital platform for advancing the field of pharmaceutical sciences. With an ISSN of 1567-2018 and an E-ISSN of 1875-5704, this esteemed journal focuses on all aspects of drug delivery systems, encompassing innovative research and developments that aim to improve therapeutics and patient outcomes. Operating from the United Arab Emirates, it has an impressive standing reflected in its 2023 Q2 ranking in Pharmaceutical Sciences and a notable position within the 62nd percentile in Scopus’s Pharmacology, Toxicology, and Pharmaceutics category. The journal not only acts as an essential resource for researchers and professionals but it also encourages the dissemination of knowledge among students and budding scientists. With the latest articles and reviews converging from 2004 to 2024, Current Drug Delivery remains committed to offering high-quality content that enhances understanding and sparks innovation in drug delivery mechanisms.

Drug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.